One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been ...

Bone marrow cells were isolated from 10- to 12-week-old WT or CD38 KO mice (both male and female) by washing the marrow cavity with sterile PBS. The collected bone marrow cells were filtered by 70 μm ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with relapsed/refractory multiple myeloma.

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...

Bone marrow cells were isolated from 10- to 12-week-old WT or CD38 KO mice (both male and female) by washing the marrow cavity with sterile PBS. The collected bone marrow cells were filtered by 70-μm ...

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI® reduced the risk of disease progression or death by 74 per cent compared to ...

An obvious next step in the development and growth of CAR T-cell therapies has been the jump to solid tumors. Because of ...

MitoThrive is a new doctor-formulated anti-aging supplement created by MD/PROCESS. Available exclusively online, MitoThrive ...